Marex Group’s AbbVie ABBV Stock Holding History

Marex Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,000	Closed	-$65.2M	–	1119
2026 Q1	$65.2M	Buy	+300,000	New	+$66.5M	0.41%	69

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Marex Group's ABBV Position: Q2 2026 in Review

Marex Group reduced its AbbVie (ABBV) stake by 98% in Q2 2026, selling an estimated $65.3M and leaving 5,599 shares worth $1.41M. The position accounts for 0.01% of the portfolio, ranked #438.

Marex Group first reported a position in ABBV in Q4 2022 and has held it in 13 quarters since. The position peaked at $67.2M in Q1 2026. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Marex Group held 5,599 shares of AbbVie worth $1.41M as of Q2 2026.
Marex Group sold 303,395 AbbVie shares in Q2 2026, an estimated $65.3M.
AbbVie made up 0.01% of Marex Group's portfolio in Q2 2026, its #438 holding.
Marex Group first reported a position in AbbVie in Q4 2022 and has held it in 13 quarters since.
Marex Group's AbbVie position peaked at $67.2M in Q1 2026.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.